| CAS ID: | 104987-11-3 |
| Molecular Formula: | C44H69NO12 |
| Molecular Weight: | 804 g/mol |
| Monoisotopic Mass: | 803.482 g/mol |
| Class: | Small Molecule |
| Natural Product: | No |
| Other Names: | FR-900506 | TACNI | Prograf | MODIGRAF | FK 506 | FR900506 | FK-506 | PROGRAF | ADOPORT | TACROLIMUS HYDRATE | PROTOPIC | ADVAGRAF | Protopic | ASTAGRAF XL | VIVADEX | PERIXIS | CAPEXION | TACROLIMUS | ENVARSUS | ENVARSUS XR |
| Analysis: | Drug repositioning mechanism analysis |
| InChI: | InChI=1S/C44H69NO12/c1-10-13-31-19-25(2)18-26(3)20-37(54-8)40-38(55-9)22-28(5)44(52,57-40)41(49)42(50)45-17-12-11-14-32(45)43(51)56-39(29(6)34(47)24-35(31)48)27(4)21-30-15-16-33(46)36(23-30)53-7/h10,19,21,26,28-34,36-40,46-47,52H,1,11-18,20,22-24H2,2-9H3/b25-19+,27-21+/t26-,28+,29+,30-,31+,32-,33+,34-,36+,37-,38-,39+,40+,44+/m0/s1 | See All |
| InChI Key: | QJJXYPPXXYFBGM-LFZNUXCKSA-N | |
| Smiles: | CO[C@@H]1C[C@@H](CC[C@H]1O)\C=C(/C)\[C@H]2OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@]4(O)O[C@H]([C@H](C[C@@H](C)C\C(=C\[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)\C)OC)[C@H](C[C@H]4C)OC | See All |
| Molfile: | Download |
Reference Record 1
| PubMed ID | 28669722 | Target ID | |
| Uniprot ID | Name | ||
| Model | vitro,rat | Fibrosis Disease | Epidural fibrosis |
| Process I | |||
| Process II | fibroblasts apoptosis | ||
| Process III | prevenet collagen deposition | ||
| Mechanism | Targeting miR-429 | ||
Reference Record 2
| PubMed ID | 26905810 | Target ID | |
| Uniprot ID | Name | ||
| Model | rat | Fibrosis Disease | Renal fibrosis |
| Process I | |||
| Process II | |||
| Process III | prevenet collagen deposition | ||
| Mechanism | |||
Reference Record 3
| PubMed ID | 25953736 | Target ID | |
| Uniprot ID | Name | ||
| Model | human | Fibrosis Disease | Cystic fibrosis |
| Process I | |||
| Process II | |||
| Process III | |||
| Mechanism | |||
Reference Record 4
| PubMed ID | 25769064 | Target ID | |
| Uniprot ID | Name | ||
| Model | vitro,mice | Fibrosis Disease | Fibrosis |
| Process I | |||
| Process II | |||
| Process III | prevenet collagen deposition | ||
| Mechanism | |||
Reference Record 5
| PubMed ID | 15808577 | Target ID | |
| Uniprot ID | Name | ||
| Model | rat | Fibrosis Disease | Renal fibrosis |
| Process I | |||
| Process II | |||
| Process III | prevenet collagen deposition | ||
| Mechanism | |||
Reference Record 6
Trial Record 1
| ClinicalTrial ID | NCT02096107 | Disease | Renal fibrosis |
| Phase | Phase 4 | Status | Completed |
| First Received | March 26, 2014 | Last Verified | August 8, 2018 |
| Sponsor | Medical University of South Carolina | ||
Trial Record 2
| ClinicalTrial ID | NCT00260208 | Disease | Liver fibrosis |
| Phase | Phase 4 | Status | Terminated |
| First Received | December 1, 2005 | Last Verified | December 6, 2011 |
| Sponsor | Novartis Pharmaceuticals | ||
Trial Record 3
| ClinicalTrial ID | NCT01707849 | Disease | Liver fibrosis |
| Phase | Phase 3 | Status | Completed |
| First Received | October 16, 2012 | Last Verified | February 7, 2018 |
| Sponsor | Hospital Vall d'Hebron | ||
Trial Record 4
| ClinicalTrial ID | NCT00538265 | Disease | Liver fibrosis |
| Phase | Phase 4 | Status | Completed |
| First Received | October 2, 2007 | Last Verified | February 3, 2011 |
| Sponsor | University Hospital, Toulouse | ||
Trial Record 5
| ClinicalTrial ID | NCT03192657 | Disease | Pulmonary fibrosis |
| Phase | Phase 2 | Status | Not yet recruiting |
| First Received | June 20, 2017 | Last Verified | June 20, 2017 |
| Sponsor | RenJi Hospital | ||
Trial Record 6
| ClinicalTrial ID | NCT02154854 | Disease | Vascular fibrosis |
| Phase | Phase 4 | Status | Unknown |
| First Received | June 3, 2014 | Last Verified | June 3, 2014 |
| Sponsor | University Hospital, Tours | ||
Trial Record 7
| ClinicalTrial ID | NCT01860183 | Disease | Renal fibrosis |
| Phase | Phase 4 | Status | Unknown |
| First Received | May 22, 2013 | Last Verified | January 30, 2014 |
| Sponsor | Clinical Hospital Merkur | ||
Trial Record 8
| ClinicalTrial ID | NCT00896012 | Disease | Renal fibrosis |
| Phase | Phase 4 | Status | Unknown |
| First Received | May 11, 2009 | Last Verified | May 11, 2009 |
| Sponsor | University at Buffalo | ||
Trial Record 9
| ClinicalTrial ID | NCT00975663 | Disease | Cystic fibrosis |
| Phase | Phase 4 | Status | Terminated |
| First Received | September 11, 2009 | Last Verified | April 26, 2011 |
| Sponsor | University Hospital, Limoges | ||
Trial Record 10
| ClinicalTrial ID | NCT00637143 | Disease | Renal fibrosis |
| Phase | Phase 4 | Status | Completed |
| First Received | March 17, 2008 | Last Verified | February 16, 2017 |
| Sponsor | Astellas Pharma Inc | ||
Trial Record 11
| ClinicalTrial ID | NCT01150097 | Disease | Liver fibrosis |
| Phase | Phase 3 | Status | Completed |
| First Received | June 24, 2010 | Last Verified | November 7, 2018 |
| Sponsor | Novartis Pharmaceuticals | ||
Trial Record 12
| ClinicalTrial ID | NCT00622869 | Disease | Liver fibrosis |
| Phase | Phase 3 | Status | Completed |
| First Received | February 25, 2008 | Last Verified | May 27, 2013 |
| Sponsor | Novartis Pharmaceuticals | ||
| PubChem: | 445643 |
| ChEMBL: | CHEMBL269732 |